272 related articles for article (PubMed ID: 19926582)
1. Tissue microarray for routine analysis of breast biomarkers in the clinical laboratory.
Thomson TA; Zhou C; Chu C; Knight B
Am J Clin Pathol; 2009 Dec; 132(6):899-905. PubMed ID: 19926582
[TBL] [Abstract][Full Text] [Related]
2. Tissue microarray technology in the routine assessment of HER-2 status in invasive breast cancer: a prospective study of the use of immunohistochemistry and fluorescence in situ hybridization.
Graham AD; Faratian D; Rae F; Thomas JS
Histopathology; 2008 Jun; 52(7):847-55. PubMed ID: 18494613
[TBL] [Abstract][Full Text] [Related]
3. Validation of tissue microarray technology in malignant peripheral nerve sheath tumours.
Cunha KS; Caruso AC; Gonçalves AS; Bernardo VG; Pires AR; da Fonseca EC; de Faria PA; da Silva LE; Geller M; de Moura-Neto RS; Lopes VS
J Clin Pathol; 2009 Jul; 62(7):629-33. PubMed ID: 19318344
[TBL] [Abstract][Full Text] [Related]
4. c-erbB-2 (HER-2/neu) immunohistochemistry in invasive breast cancer: is there concordance between standard sections and tissue microarrays?
Selvarajan S; Tan SY; Sii LH; Tan PH
Pathology; 2006 Aug; 38(4):316-20. PubMed ID: 16916720
[TBL] [Abstract][Full Text] [Related]
5. Miniature tissue microarrays for HercepTest standardisation and analysis.
Gulmann C; Loring P; O'Grady A; Kay E
J Clin Pathol; 2004 Nov; 57(11):1229-31. PubMed ID: 15509692
[TBL] [Abstract][Full Text] [Related]
6. Rapid screening of tissue microarrays for Her-2 fluorescence in situ hybridization testing is an accurate, efficient and economic method of providing an entirely in situ hybridization-based Her-2 testing service.
Faratian D; Graham A; Rae F; Thomas J
Histopathology; 2009 Mar; 54(4):428-32. PubMed ID: 19309394
[TBL] [Abstract][Full Text] [Related]
7. Tissue microarrays: construction and uses.
Fowler CB; Man YG; Zhang S; O'Leary TJ; Mason JT; Cunningham RE
Methods Mol Biol; 2011; 724():23-35. PubMed ID: 21370004
[TBL] [Abstract][Full Text] [Related]
8. Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray.
Parker RL; Huntsman DG; Lesack DW; Cupples JB; Grant DR; Akbari M; Gilks CB
Am J Clin Pathol; 2002 May; 117(5):723-8. PubMed ID: 12090420
[TBL] [Abstract][Full Text] [Related]
9. Validation of tissue microarray technology in endometrioid cancer of the endometrium.
Fons G; Hasibuan SM; van der Velden J; ten Kate FJ
J Clin Pathol; 2007 May; 60(5):500-3. PubMed ID: 16822874
[TBL] [Abstract][Full Text] [Related]
10. Quality aspects of the tissue microarray technique in a population-based cohort with ductal carcinoma in situ of the breast.
Wärnberg F; Amini RM; Goldman M; Jirström K
Histopathology; 2008 Dec; 53(6):642-9. PubMed ID: 19076680
[TBL] [Abstract][Full Text] [Related]
11. Tissue microarrays compared with whole sections and biochemical analyses. A subgroup analysis of DBCG 82 b&c.
Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Andersen J; Overgaard J
Acta Oncol; 2008; 47(4):591-9. PubMed ID: 18465327
[TBL] [Abstract][Full Text] [Related]
12. Tissue microarray validation: a methodologic study with special reference to lung cancer.
Karlsson C; Bodin L; Piehl-Aulin K; Karlsson MG
Cancer Epidemiol Biomarkers Prev; 2009 Jul; 18(7):2014-21. PubMed ID: 19531681
[TBL] [Abstract][Full Text] [Related]
13. Utility of cytology microarray constructed from effusion cell blocks for immunomarker validation.
Pu RT; Giordano TJ; Michael CW
Cancer; 2008 Oct; 114(5):300-6. PubMed ID: 18798226
[TBL] [Abstract][Full Text] [Related]
14. Implementation of TMA and digitalization in routine diagnostics of breast pathology.
Rossing HH; Talman ML; Laenkholm AV; Wielenga VT
APMIS; 2012 Apr; 120(4):341-7. PubMed ID: 22429216
[TBL] [Abstract][Full Text] [Related]
15. Tissue microarray construction from gross specimens: development of a novel simple technique.
Sharma SK; Deka L; Gupta R; Gupta S; Singh DK; Singh S
J Clin Pathol; 2010 Sep; 63(9):782-5. PubMed ID: 20696683
[TBL] [Abstract][Full Text] [Related]
16. The manufacture and assessment of tissue microarrays: suggestions and criteria for analysis, with breast cancer as an example.
Pinder SE; Brown JP; Gillett C; Purdie CA; Speirs V; Thompson AM; Shaaban AM;
J Clin Pathol; 2013 Mar; 66(3):169-77. PubMed ID: 23087330
[TBL] [Abstract][Full Text] [Related]
17. An agarose matrix facilitates sectioning of tissue microarray blocks.
Yan P; Seelentag W; Bachmann A; Bosman FT
J Histochem Cytochem; 2007 Jan; 55(1):21-4. PubMed ID: 16899763
[TBL] [Abstract][Full Text] [Related]
18. Construction of tissue microarrays using pre-existing slides as source of tissue when paraffin blocks are unavailable.
Deng FM; Zhao Y; Kong X; Lee P; Melamed J
J Clin Pathol; 2013 Jul; 66(7):627-9. PubMed ID: 23476078
[TBL] [Abstract][Full Text] [Related]
19. Tissue microarray technology in the routine assessment of HER2 status in invasive breast cancer.
Cryan J; O'Grady A; Allen D; Kay E
Histopathology; 2009 Jun; 54(7):901. PubMed ID: 19635107
[No Abstract] [Full Text] [Related]
20. Insulin-like growth factor-binding protein-3 in breast cancer: analysis with tissue microarray.
Sheen-Chen SM; Zhang H; Huang CC; Tang RP
Anticancer Res; 2009 Apr; 29(4):1131-5. PubMed ID: 19414355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
